TABLE 3.
Lymph Node Analyses and Staging for Invasive PM
| Parameter | All Patients | Patients Aged ≤10 Years |
Patients Aged >10 Years to ≤20 Years |
Patients Aged >20 Years |
|
|---|---|---|---|---|---|
| Lymph node evaluation |
Observation | 121 (36.6%) | 2 (8.7%) | 107 (37.0%) | 12 (63.2%) |
| No SLNB, LND+ | 30 (9.1%) | 1 (4.4%) | 27 (9.3%) | 2 (10.5%) | |
| SLNB− | 126 (38.1%) | 11 (47.8%) | 112 (38.8%) | 3 (15.8%) | |
| SLNB+, no LND | 5 (1.5%) | 0 (0.00%) | 4 (1.4%) | 1 (5.3%) | |
| SLNB+, LND− | 31 (9.4%) | 5 (21.7%) | 25 (8.7%) | 1 (5.3%) | |
| SLNB+, LND+ | 18 (5.4%) | 4 (17.4%) | 14 (4.8%) | 0 (0.0%) | |
| AJCC stage | I | 174 (53.7%) | 6 (25.0) | 153 (56.6%) | 15 (75.0%) |
| II | 67 (20.7%) | 7 (29.2) | 58 (20.7%) | 2 (10.0%) | |
| III | 75 (23.2%) | 10 (41.7%) | 62 (22.1%) | 3 (15.0%) | |
| IV | 8 (2.5%) | 1 (4.2) | 7 (2.5%) | 0 | |
| P = .0054 |
Abbreviations: +, positive; −, negative; AJCC, American Joint Committee on Cancer; LND, lymph node dissection, PM, pediatric melanoma; SLNB, sentinel lymph node biopsy.